Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.68 |
| ▸ | HTR2A | P28223 | 5/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002092 | 0.98 | TAAR1 (0.70) | TAAR1HTR2AHTR2CALOX5PTGS2 | |
| SCHEMBL31035919 | 0.93 | TAAR1 (0.72) | TAAR1HTR2AHTR2C | |
| SCHEMBL27001990 | 0.86 | HTR2A (0.69) | TAAR1HTR2AHTR2C | |
| SCHEMBL29376427 | 0.85 | TAAR1 (0.78) | TAAR1HTR2AHTR2C | |
| SCHEMBL2562751 | 0.85 | TAAR1 (0.78) | TAAR1HTR2AHTR2C | |
| SCHEMBL21240834 | 0.84 | TAAR1 (0.83) | TAAR1HTR2AHTR2C | |
| SCHEMBL27001997 | 0.84 | HTR2A (0.71) | TAAR1HTR2AHTR2C | |
| SCHEMBL24119648 | 0.82 | HTR2A (0.61) | TAAR1HTR2AHTR2CALOX5PTGS2 | |
| SCHEMBL29373743 | 0.81 | TAAR1 (1.00) | TAAR1HTR2AHTR2C | |
| SCHEMBL1047455 | 0.81 | TAAR1 (1.00) | TAAR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117642379-A | Phenylalkylamines and methods of making and using the same | 吉尔伽美什制药公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4305019-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192781-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | TAAR1 226/4885HTR2A 11/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.